Beckman Coulter

The flow cytometry-based assays were developed by Menlo Park, California-based IncellDx to run on Beckman Coulter instrumentation.

The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.

Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.

The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.

Cytobank provides a cloud- and machine learning-based software platform for multi-parametric single-cell data analysis, sharing, and archiving.

The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.

Labcyte has developed an acoustic droplet ejection technology called Echo that uses sound energy for the contactless transfer of samples and reagents.

The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.

The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.

Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.